Alzheimer's Treatment Centers of America
Rheumatologist– Healthcare Executive Advisory Board Member
Alzheimer's Treatment Centers of America, New York, New York, United States
About Alzheimer’s Treatment Centers of America (ATCA)
Alzheimer’s Treatment Centers of America uses Artificial Intelligence (AI) + Personalized Precision Medicine to transform the treatment of Alzheimer’s disease, dementia, and brain fog from Long COVID.
This is not about research. This is about treating patients. ATCA goes beyond diagnosing Alzheimer’s and dementia to uncover and address root causes through our innovative treatment protocols.
Our multidisciplinary team, which includes top business executives and medical professionals with expertise in virtual reality and artificial intelligence, is leading the rollout of ATCA Clinics across the U.S.
Why Now?
Immediate Revenue: ATCA is expanding to a multi-clinic organisation incorporating a new prime location...We're Launching Our New Clinic in Palm Beach Gardens, Florida. The Alzheimer's Treatment Centers of America ATCA clinic Palm Beach Gardens/Jupiter is located on the first floor of a two storey building with the Cleveland Clinic as a neighboring tenant. It is located in one of the most affluent areas and has replaced a prior urgent care space which has resulted in high levels of uptake with appointments already booked as far as March.
In-Network with Insurance: ATCA treatments are covered by Medicare, Medicare Advantage, and most major healthcare insurance providers.
Proven Results: In a study using the AI protocol implemented by ATCA, 75% of patients with mild cognitive impairment experienced no further decline.
FDA-Approved Treatment: Includes TB006, which is FDA-approved for compassionate use and has the potential to reverse dementias, including Alzheimer’s.
Physician-Supported: ATCA’s protocols are backed by an experienced Medical Advisory Board of top doctors and scientists. See our Medical Advisory Board:
https://atca.ai/medical-advisory-board/ Key Achievements Proven AI Protocol: Combines cutting-edge AI and precision medicine to deliver highly personalized treatment solutions. Scalable Model: Clinics are designed to deliver a 44% EBITDA margin, supported by strong unit economics. Market Opportunity: The U.S. Alzheimer’s treatment market is valued at $355 billion, with a global opportunity of $1.5 trillion. Research-Driven Care: Clinics also serve as micro-research facilities to advance innovation and generate future revenue streams. Rheumatologist Job Description ATCA is seeking an accomplished Rheumatologist to join its Medical Advisory Board and support the clinical and strategic expansion of a next-generation treatment model for Alzheimer’s disease and cognitive decline. This role is designed for senior rheumatologists who understand the growing evidence linking chronic inflammation, autoimmune activity, immune dysregulation, and systemic inflammatory burden to neurodegenerative disease. As a Rheumatologist Advisor, you will help shape how inflammatory and autoimmune drivers are identified and addressed within ATCA’s AI-driven precision medicine framework. You will work closely with ATCA’s executive leadership, neurologists, internists, endocrinologists, and data science teams to refine treatment pathways that incorporate immune system insights into individualized, root-cause-focused cognitive care. Responsibilities Include Clinical Strategy & Oversight: Provide expert guidance on the evaluation and management of autoimmune and inflammatory conditions that may contribute to Alzheimer’s disease, dementia, and mild cognitive impairment. Inflammation & Immune Integration: Advise on incorporating inflammatory markers, autoimmune profiles, and immune-related diagnostics into individualized treatment protocols. Precision Medicine Integration: Guide how rheumatologic biomarkers and longitudinal immune data should inform AI-assisted treatment decisions within ATCA’s precision medicine platform. Care Pathway Development: Support the development of multidisciplinary care pathways that align rheumatologic management with neurological, metabolic, and cardiovascular interventions. Quality & Outcomes Review: Review aggregated, de-identified patient outcomes to ensure safety, effectiveness, and continuous improvement in inflammation-related aspects of care across clinics. Interdisciplinary Collaboration: Collaborate with physicians, pharmacists, technologists, and executive leadership to ensure immune and inflammatory factors are addressed within scalable care models. Innovation Support: Provide insight into emerging rheumatology research, immunomodulatory therapies, and inflammatory disease management approaches that may enhance ATCA’s clinical offerings and long-term roadmap.
Why Join Us? Transform Patient Outcomes: Help advance a model of Alzheimer’s care that prioritizes early detection, prevention, and coordinated primary care involvement. Influence National Care Delivery: Play a meaningful role in shaping how primary care–informed cognitive care is delivered across a growing network of clinics nationwide. Collaborate with Leaders: Work alongside a world-class team of physicians, scientists, AI experts, and healthcare executives. Be Part of a Defining Moment: Join ATCA at a critical stage of expansion where primary care leadership directly impacts growth, outcomes, and legacy. Compensation / Perks Equity Options: Receive stock options in recognition of your clinical leadership and advisory contributions to ATCA’s mission. Investment Access: Select advisory board members may be offered access to ATCA’s current financing round. Participation is optional and independent of the advisory role. Equal Opportunity Commitment ATCA is committed to fostering an inclusive environment. We believe diversity drives innovation and welcome individuals from all backgrounds to join us in transforming Alzheimer’s treatment.
https://atca.ai/medical-advisory-board/ Key Achievements Proven AI Protocol: Combines cutting-edge AI and precision medicine to deliver highly personalized treatment solutions. Scalable Model: Clinics are designed to deliver a 44% EBITDA margin, supported by strong unit economics. Market Opportunity: The U.S. Alzheimer’s treatment market is valued at $355 billion, with a global opportunity of $1.5 trillion. Research-Driven Care: Clinics also serve as micro-research facilities to advance innovation and generate future revenue streams. Rheumatologist Job Description ATCA is seeking an accomplished Rheumatologist to join its Medical Advisory Board and support the clinical and strategic expansion of a next-generation treatment model for Alzheimer’s disease and cognitive decline. This role is designed for senior rheumatologists who understand the growing evidence linking chronic inflammation, autoimmune activity, immune dysregulation, and systemic inflammatory burden to neurodegenerative disease. As a Rheumatologist Advisor, you will help shape how inflammatory and autoimmune drivers are identified and addressed within ATCA’s AI-driven precision medicine framework. You will work closely with ATCA’s executive leadership, neurologists, internists, endocrinologists, and data science teams to refine treatment pathways that incorporate immune system insights into individualized, root-cause-focused cognitive care. Responsibilities Include Clinical Strategy & Oversight: Provide expert guidance on the evaluation and management of autoimmune and inflammatory conditions that may contribute to Alzheimer’s disease, dementia, and mild cognitive impairment. Inflammation & Immune Integration: Advise on incorporating inflammatory markers, autoimmune profiles, and immune-related diagnostics into individualized treatment protocols. Precision Medicine Integration: Guide how rheumatologic biomarkers and longitudinal immune data should inform AI-assisted treatment decisions within ATCA’s precision medicine platform. Care Pathway Development: Support the development of multidisciplinary care pathways that align rheumatologic management with neurological, metabolic, and cardiovascular interventions. Quality & Outcomes Review: Review aggregated, de-identified patient outcomes to ensure safety, effectiveness, and continuous improvement in inflammation-related aspects of care across clinics. Interdisciplinary Collaboration: Collaborate with physicians, pharmacists, technologists, and executive leadership to ensure immune and inflammatory factors are addressed within scalable care models. Innovation Support: Provide insight into emerging rheumatology research, immunomodulatory therapies, and inflammatory disease management approaches that may enhance ATCA’s clinical offerings and long-term roadmap.
Why Join Us? Transform Patient Outcomes: Help advance a model of Alzheimer’s care that prioritizes early detection, prevention, and coordinated primary care involvement. Influence National Care Delivery: Play a meaningful role in shaping how primary care–informed cognitive care is delivered across a growing network of clinics nationwide. Collaborate with Leaders: Work alongside a world-class team of physicians, scientists, AI experts, and healthcare executives. Be Part of a Defining Moment: Join ATCA at a critical stage of expansion where primary care leadership directly impacts growth, outcomes, and legacy. Compensation / Perks Equity Options: Receive stock options in recognition of your clinical leadership and advisory contributions to ATCA’s mission. Investment Access: Select advisory board members may be offered access to ATCA’s current financing round. Participation is optional and independent of the advisory role. Equal Opportunity Commitment ATCA is committed to fostering an inclusive environment. We believe diversity drives innovation and welcome individuals from all backgrounds to join us in transforming Alzheimer’s treatment.